Lansforsakringar Fondforvaltning AB publ Purchases 3,073 Shares of Cencora, Inc. $COR

Lansforsakringar Fondforvaltning AB publ increased its holdings in Cencora, Inc. (NYSE:COR) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,254 shares of the company’s stock after purchasing an additional 3,073 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Cencora were worth $18,831,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Cornerstone Wealth Group LLC raised its position in shares of Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after buying an additional 30 shares in the last quarter. Security Financial Services INC. raised its position in Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after purchasing an additional 33 shares during the period. Hemington Wealth Management lifted its stake in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after purchasing an additional 35 shares during the last quarter. Quadcap Wealth Management LLC boosted its holdings in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after purchasing an additional 36 shares during the period. Finally, Howard Capital Management Inc. increased its position in shares of Cencora by 2.5% during the 3rd quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock valued at $468,000 after purchasing an additional 37 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 15,220 shares of company stock worth $5,282,867 over the last three months. 0.38% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on COR shares. Robert W. Baird set a $415.00 price target on Cencora in a research report on Tuesday, January 13th. Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Evercore cut their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Price Performance

Shares of COR stock opened at $360.70 on Monday. The company has a market capitalization of $70.17 billion, a P/E ratio of 43.35, a P/E/G ratio of 1.68 and a beta of 0.68. The company’s 50-day simple moving average is $349.41 and its two-hundred day simple moving average is $331.39. Cencora, Inc. has a one year low of $240.72 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same quarter in the previous year, the business earned $3.73 earnings per share. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s payout ratio is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.